Athersys, Inc. Receives Orphan Drug Designation for MultiStem in Hurler's Syndrome

There are 2 comments on the BioSpace story from Jul 10, 2012, titled Athersys, Inc. Receives Orphan Drug Designation for MultiStem in Hurler's Syndrome. In it, BioSpace reports that:

Athersys, Inc. announced today that MultiStemA , Athersys' proprietary cell therapy, has been granted orphan drug designation by the U.S. Food and Drug Administration for the treatment of Hurler's Syndrome, also known as mucopolysaccharidosis type I or MPS-I. Hurler's Syndrome is a lysosomal storage disorder that affects approximately 1 of every ... (more)

Join the discussion below, or Read more at BioSpace.

athxer

Singapore, Singapore

#1 Jul 11, 2012
any idea when a partnership for this is happening??? Don;t wish to see another dilution exercise.
athxer

Singapore, Singapore

#2 Jul 17, 2012
I'm starting to loose patience at Athersys. Whenever there's slightest bit of positive news, this damn stock will go down and remain down.

Tell me when this thread is updated:

Subscribe Now Add to my Tracker

Add your comments below

Characters left: 4000

Please note by submitting this form you acknowledge that you have read the Terms of Service and the comment you are posting is in compliance with such terms. Be polite. Inappropriate posts may be removed by the moderator. Send us your feedback.

Biotech Discussions

Title Updated Last By Comments
News Students receive expert tips on a host of subjects (Jun '09) Tue Randy Bradford 2
News Bristol Palin says abstinence best path for teens (May '09) May 14 swedenforever 2,621
News Vaccine industry has suppressed and intimidated... May 5 VACCINES MAIM KILL 1
News Oyez! Town Crier at Royal Baby Birth Captures A... May 4 Anita Bryant s Jihad 1
News Some beards are crappy because they are May 3 geri 1
News A3 adenosine receptor can activate 'off signals... Apr 25 bobb 1
News Bashful? Buy the little blue pill online (May '13) Apr '15 brianfarrel 13
More from around the web